Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 4Q Financial Reports | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

4Q Financial Reports

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck

4Q Revenues: $5.7 billion (flat)

4Q Earnings: $1.1 billion (+2%)

FY Revenues: $22 billion (-4%)

FY Earnings: $4.6 billion (-20%)

Comments: Sales growth of Singulair and Vytorin drove results for the year. Worldwide sales of Singulair reached $819 million for the quarter, up 12% and $3 billion for the year, up 13%. Global sales of Vytorin, developed and marketed by the Merck/Schering-Plough partnership, reached $355 million in the fourth quarter and $1 billion for the year. R&D expenses were $1.1 billion for the quarter, comparable to 4Q2004, and $3.8 billion for the year, down 4%. Restructuring costs were $229 million and $322 million for the quarter and full year. Results include the impact of reserving an additional $295 million in the fourth quarter for VIOXX legal defense costs.

Wyeth

4Q Revenues: $4.7 billion (+2%)

4Q Earnings: $731.7 million (loss of $1.7 billion in 4Q2004)

FY Revenues: $18.8 billion (+8%)

FY Earnings: $3.7 billion (+196%)

Comments: Enbrel and Prevnar performed strong for the quarter and the year. Enbrel sales, in North America, were $674 million for the quarter, up 19% and $2.6 billion for the year, up 35%. Prevnar achieved revenue of $401 million for the quarter, up 18% and $1.5 billion for the year, up 43%. R&D expenses were $875.7 million for the quarter, up 35% and $2.7 billion for the year, up 11%.

Elan

4Q Revenues: $140 million (+13%)

4Q Loss: $58.3 million (loss of $107.1 million 4Q2004)

FY Revenues: $490 million (+2%)

FY Loss: $383.6 million (loss of $394.7 million FY2004)

Comments: Revenue from marketed products was $65.9 million for the quarter, up 28% due to sales of Maxipime and Azactam and revenue from Prialt, which was launched in 2005, offset by a decrease in the sales of Tysabri, which was voluntarily suspended from the market in February 2005. Maxipime sales were up 57% in the quarter to $46.8 million and up 19% for the year to $140.3 million. Azactam sales were $17.5 million for the quarter, up 14% and increased 14% to $57.7 million for the year. Revenue from Prialt was $2 million for the quarter and $6.3 million for the year. R&D expenses were $52.8 million in the quarter, down 26% and flat for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters